For example, methylation signatures of selected genes, such as ALX1 in non-small-cell lung cancer (NSCLC) and RASSF1A in prostate cancer, were found to be prognostic and correlate with relapse-free survival of the patients [53], [54]. This evidence concerns the gene RASSF1 and non-small cell lung carcinoma.